Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

XPhyto: Is Mescaline the Next Big Mood-Modifying Medicine?

It has the potential to be the next frontier in the psychedelics renaissance, and it represents an unprecedented opportunity to innovate a notable advancement in mental health therapy. In anecdotal studies, mescaline has shown promise in treating depression, anxiety, PTSD,...
Marc Davis | April 6, 2021 |

Buzz on the Bullboards: One Step Closer to a Canadian-Made COVID Vaccine?

(Image via Theralase Technologies Inc.) Clinical-stage pharmaceutical company Theralase Technologies Inc. ( TSX-V: TLT , Forum ) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. In collaboration with the University of Manitoba (UM), t...
Stockhouse Editorial | February 9, 2022 |

High Returns

Download the report today!
| April 4, 2023 |

Thematica Report: Exploring the opportunities in alternative healthcare

An investor’s guide to opportunities in the alternative healthcare market. Click here to access the report.On a broad scale, the complementary and alternative medicine (CAM) market...
Jocelyn Aspa | July 13, 2022 |

The Great White North of Debt: What Canada's Monetary Policies Mean

As I sit here on a Thursday evening, contemplating the logic behind my most recent additions to a highly tentative short position on the SPY:US (the exchange-traded fund [ETF] tracking the S&P 500), I am doing everything in my power to not take my quote machine and proj...
Streetwise Reports | June 30, 2020 |

Buzz on the Bullboards – The Next Great Oil Frontier?

(Image via Crescent Point Energy.) September is often seen as a “fresh start” for the markets, like a new year on the stock exchange, but this party was met with a serious hangover in the shape of poor share performances that only just recently b...
Stockhouse Editorial | September 16, 2020 |

Novamind’s Trial Site for Merck Another Example Of Its Leadership in Mental Health

Novamind’s clinics and clinical research capabilities are already well established to bring alternative mental health therapies, including psychedelic medicine, to market. One of the world’s largest pharmaceutical companies has selected ...
Featured Submission | March 24, 2021 |

Fiscal Year 'Reads Well' for Regenerative Medicine Company

The firm's final quarter and full-year results are reviewed in a Ladenburg Thalmann report. In an Aug. 30 research note, Ladenburg Thalmann analyst Jeffrey Cohen reported Mesoblast Ltd.'s (MESO:NASDAQ; MSB:ASX) financial results for Q4/19 and fiscal year 2019 (FY19)...
Streetwise Reports | September 5, 2019 |

Novamind Selected by Merck to Advance Research for Treatment-Resistant Depression

Novamind’s subsidiary, Cedar Clinical Research, to serve as a key clinical research site Independent validation of the expertise and capabilities of Novamind in managing clinical trials Adds to established track record conducting research a...
Featured Submission | March 18, 2021 |

'Stay Tuned for Data' from Regenerative Medicine Firm with 'Blockbuster Opportunity'

The compelling aspects of this life sciences story are presented in a Dawson James report. In a Jan. 28 research note, analyst Jason Kolbert reported that Dawson James Securities increased its target price on Mesoblast Ltd. (MESO:NASDAQ; MSB:ASX) to $15 pe...
Streetwise Reports | February 3, 2020 |
1 2 3 4 5 6 7 8 9 10 ...